GlassScriptPhysician profile
Babak Morvarid
NPI 1780796292
$850.58
in general payments reported to CMS, 2019-2025
14 companies · $32.64 in 2025
The $32.64 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $316 · 2023: $23.39 · 2024: $103 · 2025: $32.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $143.75 | 2019-2020 | |
| Biogen, INC. | $118.00 | 2019-2020 | |
| Abbott Laboratories | $102.59 | 2023-2024 | Infinity |
| Amgen INC. | $99.59 | 2019-2020 | |
| Mdd US Operations, LLC | $77.43 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $73.23 | 2019-2020 | |
| Lilly USA, LLC | $41.63 | 2019 | |
| Tanabe Pharma America, INC. | $41.16 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $38.68 | 2020 | |
| Novartis Pharmaceuticals Corporation | $35.43 | 2019-2020 | |
| Abbvie INC. | $32.64 | 2025 | |
| Ceribell, INC. | $23.46 | 2024 | Pocket Eeg Device |
| Genzyme Corporation | $22.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Morvarid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.